Processa Pharmaceuticals

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Hanover, MD.

Earnings data Q4 2022

Earnings data Q1 2023

HANOVER, MD, March 23, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a developer of Next Generation Chemotherapy drugs that provide a better safety-efficacy profile than their widely used FDA-approved counterparts, today announced that it will host a conference call and live webcast on March 30, 2023 at 4:30 p.m. EST to discuss its 2022 results and provide an update on its clinical pipeline for 2023.

Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST

HANOVER, MD, March 17, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a developer of Next Generation Chemotherapies (NGCs), today announced that the Company has dosed the first patient in its NGC-Capecitabine (combination of PCS6422 and capecitabine) 300 mg dose group. The Processa NGCs already have clinical evidence to support their safety and efficacy while they target patients who need better treatment options for their cancer in order to improve survival and/or quality of life.

Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine

HANOVER, MD, March 07, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), the developer of the Next Generation Chemotherapy drugs that will provide a better safety-efficacy profile than their widely used FDA-approved counterparts, today announced that the Company's President & CEO, Dr. David Young, will present virtually at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023 at 12:00 PM Eastern. The company is looking forward to sharing its progress on key programs and upcoming data milestones.

Processa Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

HANOVER, MD, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”) reiterates the strategic prioritization of its pipeline of proprietary oncology drugs, defined as Next Generation Chemotherapies (NGCs). Previous studies with these NGCs suggest potential improvement in the safety-efficacy profile will significantly differentiate these NGCs from their three presently widely used counterparts - capecitabine, gemcitabine, and irinotecan.

Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies

HANOVER, MD., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a diversified clinical-stage company developing next generation chemotherapy drugs for patients who have unmet medical conditions and/or require better treatment options to improve a patient's survival and/or quality of life, today announced that it has closed its $6.25 million registered direct offering entered into definitive agreements with retail investors and insiders for the purchase and sale of 7,812,544 common shares at a purchase price of $0.80 per share.

Processa Pharmaceuticals, Inc. Announces Closing of $6.25 Million Registered Direct Offering, Which Included Retail Investors and Insiders, Priced at the Market Under Nasdaq Rules

HANOVER, MD., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a diversified clinical-stage company developing next generation chemotherapy drugs for patients who have unmet medical conditions and/or require better treatment options to improve a patient's survival and/or quality of life, today announced that it has entered into definitive agreements with retail investors for the purchase and sale of 7,812,544 common shares at a purchase price of $0.80 per share in a registered direct offering priced at the market under the Nasdaq rules. The closing of the offering is expected to occur on or about February 14, 2023, subject to the satisfaction of customary closing conditions.

Processa Pharmaceuticals, Inc. Announces $6.25 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

HANOVER, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), Dr. David Young, Processa Pharmaceuticals, CEO will present an update on Processa's future therapeutic focus and strategy at the upcoming Biotech Showcase on January 11, 2023, at 10 am. This presentation will also be accessible at https://event.webcasts.com/starthere.jsp?ei=1591773&tp_key=fbb2da9fa8

Processa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023.

HANOVER, MD, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a diversified clinical-stage company developing products to improve survival and/or the quality of life for patients who have an unmet medical need condition, today announced positive top-line results on the clinical symptoms associated with gastroparesis from a 4-week Phase 2A study of PCS12852, which is being developed for the treatment of patients with gastroparesis. The trial was a placebo-controlled, randomized, dose-response study designed to evaluate the safety, efficacy, and pharmacokinetics of two dosage regimens of PCS12852 vs placebo (clinicaltrials.gov identifier NCT05270460). Processa previously announced an improvement in the primary endpoint of the study, the gastric emptying rate, in patients that received a 0.5 mg daily dose of PCS12852. The results from this Phase 2A study also showed that clinically meaningful improvements in gastroparesis symptoms occurred in more patients (i.e., a greater percentage of patients) receiving the PCS12852 0.5 mg daily dose than the placebo daily dose.

Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Jim Stanker - CFO David Young - President & CEO Conference Call Participants Francois Brisebois - Oppenheimer Naz Rahman - Maxim Group Operator Greetings, and welcome to Processa Pharmaceuticals third-quarter 2022 earnings call and corporate update. At this time, all participants are in a listen-only mode.

Processa Pharmaceuticals, Inc. (PCSA) Q3 2022 Earnings Call Transcript

HANOVER, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a diversified clinical-stage company developing drugs for patients who have unmet medical conditions and/or require better treatment options to improve a patient's survival and/or quality of life, today announced financial results for the quarter ended September 30, 2022, and provided an update on its clinical programs.

Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update

HANOVER, MD, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host a conference call and live webcast on November 8, 2022, at 4:30 p.m. EST to discuss its third quarter 2022 results and provide an update on its clinical pipeline.

Processa Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2022 Results and Provide Drug Development Update on November 8, 2022 at 4:30 p.m. EST

Next Generation Capecitabine (NGC) D osage R egimens H ave B een I dentified I n T he O ngoing Phase 1B T rial W ith P otentially B etter S afety A nd E fficacy P rofiles T han E xisting C hemotherapy

Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial

HANOVER, MD, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), (“Processa” or “Company”), a clinical stage biopharmaceutical company focused on developing products to improve survival and/or quality of life for patients who have an unmet medical need condition for which there are few or no therapeutic options, today provided an update on enrollment across all its clinical programs.

Processa Pharmaceuticals Provides Update on Enrollment Across all Clinical Programs

HANOVER, MD, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition today announced that Dr. Dr. David Young, Chief Executive Officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 14, 2022.

Processa Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 12-14, 2022

Board A ppointments Designed to Position Company for Anticipated Milestones While Ensuring Adherence to the Highest Governance Standards

Processa Pharmaceuticals Appoints Khoso Baluch and James Neal to its Board of Directors and Justin Yorke to Chairman of the Board

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants James Stanker - Chief Financial Officer David Young - President and Chief Executive Officer Conference Call Participants François Brisebois - Oppenheimer & Co. Inc. Naz Rahman - Maxim Group LLC Operator Good afternoon, ladies and gentlemen, and welcome to the Processa Pharmaceuticals Second Quarter 2022 Earnings Call. At this time, all participants have been placed on a listen-only mode, and we will open the floor for your questions and comments after the presentation.

Processa Pharmaceuticals, Inc. (PCSA) CEO David Young on Q2 2022 Results - Earnings Call Transcript

HANOVER, Md., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical conditions and/or require better treatment options to improve a patient's survival and/or quality of life, today announced financial results for the quarter ended June 30, 2022, and provided an update on its clinical programs.

Processa Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update

HANOVER, MD, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host a conference call and live webcast on August 11, 2022, at 4:30 p.m. EST to discuss its second quarter 2022 results and provide an update on its clinical pipeline.

Processa Pharmaceuticals to Host Conference Call to Discuss Its Second Quarter 2022 Results and Provide 2nd Half Clinical Pipeline Update on August 11, 2022, at 4:30 p.m. EST

HANOVER, MD, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical need conditions, announces today that it has launched a new website Necrobiosislipoidicastudy.com. The website is designed to increase awareness of ulcerative Necrobiosis Lipoidica (“uNL”), an extremely rare condition, and to inform patients about the ongoing Phase 2 study that is investigating the use of PCS499 for the treatment of this rare condition.

Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499

HANOVER, MD, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical need conditions, announces today that it has launched a new website Necrobiosislipoidicastudy.com. The website is designed to increase awareness of ulcerative Necrobiosis Lipoidica (“uNL”), an extremely rare condition, and to inform patients about the ongoing Phase 2 study that is investigating the use of PCS499 for the treatment of this rare condition.

Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499

HANOVER, MD., July 12, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage biopharmaceutical company developing drugs to improve the survival and/or quality of life for patients who have unmet medical conditions announced today that Dr. David Young, it's Chief Executive Officer, will present “Thinking Regulatory First - Considerations for the Effective Development of Rare Disease Therapies” at the World Orphan Drug Congress USA 2022 Conference on Wednesday, July 13, 2022 at 3:25 pm EDT.

Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, July 11-13, 2022

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Jim Stanker – Chief Financial Officer David Young – Chief Executive Officer Conference Call Participants Robin Garner – Craig-Hallum Naz Rahman – Maxim Group Operator Greetings, and welcome to Processa Pharmaceuticals First Quarter 2022 Earnings Conference Call and Corporate Update. At this time, all participants are in a listen-only mode.

Processa Pharmaceuticals' (PCSA) CEO David Young on Q1 2022 Results - Earnings Call Transcript

HANOVER, Md., May 12, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient's survival and/or quality of life, today announced financial results for the quarter ended March 31, 2022, and provided an update on its clinical programs.

Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update

Processa f ocuse s on i dentify ing the PCS6422 regimens to i ncrease c apecitabine potency while identifying the MTD of Next Generation Capecitabine

Processa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine)

HANOVER, MD, April 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need, announced today that it has enrolled its first patient in the Phase 2A clinical trial of PCS12852 in patients with moderate to severe gastroparesis. Gastroparesis is a chronic gastric motility disorder in which the stomach does not empty food as quickly as it should, resulting in potentially serious forms of heartburn, nausea, vomiting, and bloating for millions of patients in the U.S. As such gastroparesis is recognized to be a serious unmet medical need condition for which patients need alternative treatment options.

News for Processa Pharmaceuticals Stock (PCSA)